Sienna Biopharmaceuticals Files for Bankruptcy, Delaying Phase III Psoriasis Trial | BioSpace
Southern California-based Sienna Biopharmaceuticals filed for bankruptcy Tuesday, which sent share prices tumbling more than 73%. The dermatological drug maker will use Chapter 11 protection to restructure the company, including a possible sale of assets, and will delay development of its Phase III-ready psoriasis treatment. Frederick C.
Sienna Biopharmaceuticals to shut down by end of week
Sienna Biopharmaceuticals will close by the end of this week and lay off its remaining employees after it failed to sell itself out of bankruptcy, according to Bankrupt Company News. The Westlake Village, Calif.-based biopharmaceutical company filed for Chapter 11 bankruptcy in September after several of its drugs failed to gain approval.